[Nephro-protection: role of arterial pressure in progression of renal pathology. Does a nephro-protective effect depend on the choice of antihypertensive drug?].
Shestakova
M V
MV
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D004232:Diuretics / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000517:prevention & control; D015337:Multicenter Studies as Topic; D011379:Prognosis; D012307:Risk Factors; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D000804:Angiotensin II
Nefroprotektsiia: rol' arterial'nogo davleniia v progressirovanii patologii pochek. Zavisit li nefroprotektivnyĭ éffekt ot vybora antigipertenzivnogo preparata?